Xinyu Yu

Dr. Xinyu Yu

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 August 2025 in Nature Communications
Verified
Journal Article
Open access
PDF file
XYXinyu Yu
Xinyu Yu
JHJincan He
Jincan He
CWChanghong Wang
Changhong Wang
JMJianbing Mu
Jianbing Mu
XCXuan Chen
Xuan Chen
QZQingfeng Zhang
Qingfeng Zhang
Artemisinin and its semisynthetic derivatives (ART) are crucial medicines in artemisinin-based combination therapies worldwide. Despite ART’s efficacy, small proportions of young intraerythrocytic ring stage parasites can survive the drug’s short half-life, and dormant forms can cause recrudescence if not cleared by partner drugs. Certain mutations in the Kelch propeller region of P. falciparum protein (PfK13) are linked to the higher ring-stage survival (RS), which above 1% can be a feature of ‘artemisinin partial resistance’. Emerging evidence indicates epigenetic modulators may contribute to RS. Here, we report systematic evaluations of all putative histone acetyltransferases (HATs) of P. falciparum in 30 culture-adapted field isolates and 43 subcloned field isolates. Only PfMYST shows a full association with RS phenotype modulations. Knockdown experiments confirm the linkage of Pfmyst expression to these modulations, with evidence of altered metabolic processes. Through single-cell RNA sequencing, ChIP-seq analysis, and CRISPR/cas9 genetic manipulation, PfMYST-targeted RS-related genes have been identified and functionally validated. Multi-omics analysis indicates significant interplay of PfMYST and PfK13 mechanisms in RS. PfMYST epigenetic modulation extends to other antimalarials, including amodiaquine, pyrimethamine, chloroquine, and pyronaridine. Collectively, our findings provide important information on the epigenetic regulatory mechanism of P. falciparum RS after pulses of ART and other antimalarials.

11 February 2026 in mBio
Verified
Journal Article
Open access
YWYijie Wang
Yijie Wang
XYXinyu Yu
Xinyu Yu
XZXinyu Zhang
Xinyu Zhang
XHXiaohui He
Xiaohui He
YTYongxin Tang
Yongxin Tang
JCJun Cao
Jun Cao
Artemisinin antimalarial drugs initially exhibited remarkable efficacy against Plasmodium falciparum . However, their poor solubility and low bioavailability necessitate high doses and lead to an extremely short in vivo half-life. These limitations not only drive the emergence of drug-resistant Plasmodium strains but also compromise long-term therapeutic outcomes. Herein, we report a zein-based sustained release formulation, wherein zein, a natural maize protein, serves as a biocompatible nanocarrier to effectively encapsulate artemisinin (ART). Notably, this nanocarrier formulation achieves a 200-fold enhancement in ART’s water solubility, addressing a key bottleneck of ART-based therapies. In vitro assays confirm that the zein-based formulation allows for the sustained release of ART, which could help maintain therapeutic concentrations over extended periods and displayed different release rates and good dispersibility in both acid and basic environments. Importantly, in vitro evaluations also demonstrate that the nanoformulation exerts potent inhibitory effects against ART-resistant P. falciparum strains in both ring survival assay and recrudescence assay, attributed to the sustained maintenance of effective ART concentrations. In vivo studies, utilizing both rodent malaria models and humanized erythrocyte mouse models, further validate the nanoformulation’s therapeutic potential. The zein nanocarrier significantly prolongs ART’s in vivo half-life via its sustained-release capability, thereby maintaining effective blood concentrations over an extended duration. Compared to free ART, the nanoformulation exhibits superior efficacy in reducing parasitemia, preventing malaria recrudescence, and, most notably, overcoming ART resistance in drug-resistant Plasmodium infections. Collectively, these findings establish the zein-based nanocarrier as a promising strategy to optimize ART-based therapies by addressing solubility and pharmacokinetic limitations while effectively combating drug-resistant malaria. IMPORTANCE: Half of the world’s population is at risk of malaria infection, and artemisinin (ART) turns out to be a powerful medicine for malaria control. The rapid emergence and global spread of resistance to ART have led to a significantly increasing clinical treatment failure rate worldwide. A critical limitation of ART is its extremely short blood half-life (~1 h), which results in rapid declines in plasma drug concentrations below therapeutic thresholds. Some parasites may switch into a “dormant” form, which is less sensitive to ART, resulting in recrudescence following treatment. Thus, developing a sustained-release formulation provides a promising solution to prolong the in vivo half-life of ART. Additionally, its relatively low solubility restricts its in vivo bioavailability, primarily due to the limited dissolution and absorption of the compound in aqueous biological environments. In this study, we prepared a zein-based sustained-release formulation of ART for oral and intraperitoneal administration. Our results indicate that this zein-based sustained release nanoformulation not only significantly improves ART’s water solubility (a key barrier to its bioavailability) but also extends its in vivo half-life via controlled drug release. Importantly, the prolonged half-life ensures sustained therapeutic ART concentrations, directly enhancing the formulation’s ability against ART-resistant P. falciparum strains. Collectively, these results highlight the formulation’s substantial potential for clinical application in improving ART-based antimalarial therapy.

18 December 2025 in Microorganisms
Verified
Journal Article
Open access
PDF file
CXChen Xingyu
Chen Xingyu
XHXiaohui He
Xiaohui He
YWYanmin Wang
Yanmin Wang
YFYangping Feng
Yangping Feng
ZWZihan Wang
Zihan Wang
YXYunchang Xie
Yunchang Xie
The endophytic Streptomyces sp. PRh3 (PRh3), isolated from Dongxiang wild rice (DXWR), exhibited impaired biosynthetic capacity in the laboratory. To address this defect, rifampicin-based ribosome engineering was first applied to PRh3 to generate PRh3-r55, which acquired a characteristic H473Y rifampicin-resistant mutation in rpoB to activate the production of two β-carboline alkaloids JBIR-133 and JBIR-134. Then the biosynthetic gene cluster (BGC) ksl was introduced into PRh3-r55 for heterologous expression, generating PRh3-r55K. This combined approach achieved a synergistic effect, enabling the strain to produce not only the expected JBIR-133, JBIR-134, and kitasetaline, but also a novel sulfur-containing molecule, novkitasetaline. Structural elucidation identified novkitasetaline as a unique tryptamine-substituted kitasetaline derivative at the C-3 position of its pyridine ring. Notably, this structural modification conferred significant antimalarial activity to novkitasetaline, rendering it active against drug-sensitive Plasmodium falciparum 3D7 (IC50 = 32.65 ± 2.93 μM) and three other drug-resistant P. falciparum strains: K13C580Y, Dd2, and HB3 (IC50 = 45.98 ± 4.17~59.67 ± 3.15 μM), primarily by disrupting late-stage parasite development. These efforts not only identified a promising antimalarial lead compound but also demonstrated that combining ribosome engineering with heterologous expression is an effective strategy for discovering bioactive natural products from Streptomyces.

2 June 2026 in Microbiology Spectrum
Verified
Journal Article
Open access
YTYongxin Tang
Yongxin Tang
XZXinyu Zhang
Xinyu Zhang
XHXiaohui He
Xiaohui He
TJTao Jiang
Tao Jiang
JCJun Cao
Jun Cao
XYXinyu Yu
Xinyu Yu
In this study, paclitaxel (PTX), a well-characterized microtubule-stabilizing agent, was systematically investigated for its antimalarial potential against drug-resistant Plasmodium falciparum. In vitro experiments demonstrated that PTX potently inhibits intraerythrocytic development of drug-sensitive and -resistant strains, including chloroquine-resistant and artemisinin-resistant parasite lines, with 72-h half-maximal inhibitory concentrations (IC₅₀) ranging from 83.67 to 92.75 nM. PTX arrests parasite schizogony and reduces merozoite formation by ~25.69% to 37.46% when exposed to the trophozoite/schizont stage. Meanwhile, time-dependent drug activity against gametocyte maturation demonstrated that treatment during the immature gametocyte stages elicited a significant reduction in final gametocytemia (~38.24% to 58.79%), thereby validating the dual-targeting potential of PTX against both the pathogenic asexual and transmission-competent sexual parasite stages. Molecular dynamics simulations suggested that PTX was capable of binding to P. falciparum β-tubulin and potentially induced structural perturbations, including complex stabilization, enhanced M-loop flexibility, and global compaction, which may, in turn, disrupt microtubule dynamics. These results provide a plausible molecular basis for the antimalarial mechanism of PTX. Critically, PTX exhibits robust synergism with dihydroartemisinin (DHA) against artemisinin-resistant strains, reducing ring-stage survival to 1% and addressing the global challenge of artemisinin resistance. In vivo assays revealed that the PTX-DHA combination achieves near-complete parasite clearance (96% in humanized P. falciparum models. This finding confirms PTX’s translational potential and positions it as a novel tubulin-targeting partner for DHA, offering a promising strategy to combat drug-resistant malaria while safeguarding the efficacy of artemisinin-based combination therapies. IMPORTANCE: In the current landscape of next-generation antimalarial development, preference will be given to compounds with activity against emerging drug-resistant parasite strains. However, identifying such effective molecules through traditional diversity library screenings remains challenging. As a result, the repurposing of old drugs has emerged as a prevalent and pragmatic strategy in the search for novel antimalarial agents. Our findings highlight a significant enhancement in combinatorial therapeutic efficacy, positioning paclitaxel as a promising partner drug for overcoming emerging drug resistance in malaria parasites. Therefore, we believe that this work will confer a broad interest to the readers of different disciplines, including antimalarial development.